타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Zeprumetostat | Vincristine Sulfate Liposome | Vevoctadekin | Verapamil Hydrochloride |
Overview Company | Roche / Genentech | Sun Yat-sen University | M.D. Anderson Cancer Center | Simcha Therapeutics | Bristol-Myers Squibb |
Overview Modality | ADC | CGT | ANTIBODY | CGT | ADC |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | Mature T-cell and NK-cell Lymphoma | Recurrent Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | — | — | — | — |
MoA Biomarker | CD20 expression | — | — | — | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — | — | — |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
Preclinical Animal (cat.) | Rat | — | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Zeprumetostat | Vincristine Sulfate Liposome | Vevoctadekin | Verapamil Hydrochloride |
Overview Company | Roche / Genentech | Sun Yat-sen University | M.D. Anderson Cancer Center | Simcha Therapeutics | Bristol-Myers Squibb |
Overview Modality | ADC | CGT | ANTIBODY | CGT | ADC |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | Mature T-cell and NK-cell Lymphoma | Recurrent Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | — | — | — | — |
MoA Biomarker | CD20 expression | — | — | — | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | — | — | — | — |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
Preclinical Animal (cat.) | Rat | — | — | — | — |
추천 비교
추천 비교